Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)

ClinicalTrials.gov ID: NCT00197262

Public ClinicalTrials.gov record NCT00197262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Single-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 mcg for 2 Weeks in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis

Study identification

NCT ID
NCT00197262
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
288 participants

Conditions and interventions

Interventions

  • GW685698X Aqueous Nasal Spray Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2005
Primary completion
Sep 30, 2005
Completion
Sep 30, 2005
Last update posted
Jan 18, 2017

2005

United States locations

U.S. sites
18
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Indianapolis Indiana 46208
GSK Investigational Site Lafayette Indiana 47904
GSK Investigational Site Louisville Kentucky 40215
GSK Investigational Site Novi Michigan 48375
GSK Investigational Site Minneapolis Minnesota 55402
GSK Investigational Site Columbia Missouri 65203
GSK Investigational Site Rolla Missouri 65401
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Lincoln Nebraska 68505
GSK Investigational Site Papillion Nebraska 68046
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Sylvania Ohio 43560
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Dallas Texas 75231-4307
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site Greenfield Wisconsin 53228
GSK Investigational Site West Allis Wisconsin 53227

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00197262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2017 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00197262 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →